Abstract
Background The increase in childhood allergic disease in recent decades has coincided with increased folic acid intakes during pregnancy. Circulating unmetabolized folic acid (UMFA) has been proposed as a biomarker of excessive folic acid intake.
Objective We aimed to determine if late-pregnancy serum UMFA and total folate concentrations were associated with allergic disease risk in the offspring at one year of age in a population at high risk of allergy.
Methods The cohort consisted of 561 mother-infant pairs from Western Australia. To be eligible the infant had a first-degree relative (mother, father or sibling) with a history of medically diagnosed allergic disease. Maternal serum was collected between 36 and 40 weeks of gestation. UMFA concentrations were measured by tandem mass spectrometry using stable isotope dilution, folate concentrations were determined using the microbiological method with standardized kits. Infant allergic disease outcomes of medically diagnosed eczema, steroid treated eczema, atopic eczema, IgE-mediated food allergy, allergen sensitization and medically diagnosed wheeze were assessed at 1 year of age.
Results Median (IQR) for UMFA and serum folate was 1.6 (0.6-4.7) and 53.2 (32.6-74.5) nmol/L, respectively. Of the infants, 34.6% had medically diagnosed eczema, 26.4% allergen sensitization and 14.9% had an IgE-mediated food allergy. In both adjusted and unadjusted models there was little evidence of association between UMFA or serum folate and any of the infant allergy outcomes.
Conclusion In this cohort of children at high risk for allergic disease there was no association between maternal UMFA or serum folate measured in late pregnancy and allergic disease outcomes at 1 year of age.
Competing Interest Statement
Prof. Makrides reports scientific board membership of Trajan, outside the submitted work. Prof. Prescott reports personal fees from Danone Nutricia, personal fees from Bayer, personal fees from Swisse Advisory Board, personal fees from Sanofi, outside the submitted work Dr. Best, Prof. Green, Ms Sulistyoningrum, Dr Sullivan, Dr. Aufreiter, Dr Skubisz, Prof. O'Connor and Dr Palmer have no conflicts of interest to disclose.
Funding Statement
This work was supported by a Thrasher Researcher Foundation Early Career Award Program Grant, the National Health and Medical Research Council (NHMRC) of Australia: Project Grant (APP1046036) and NHMRC fellowships awarded to MM (APP1061704) and DJP (APP1144544). KPB is supported by Women's and Children's Hospital Foundation, MS McLeod Post-doctoral Fellowship. DCS is supported by The Australian Government Research Training Program Scholarship from The University of Adelaide.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The original cohort study was approved by the Princess Margaret Hospital Human Research Ethics Committee (1942EP), and all participants provided written informed consent. The maternal blood analysis for this study was also approved by the Women's and Children's Health Network Human Research Ethics Committee in 2019 (HREC/19/WCHN/21).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ Last: Best, Green, Sullivan, Sulistyoningrum, Aufreiter, Prescott, Makrides, O’Connor, Skubisz, Palmer
Sources of Support: This work was supported by a Thrasher Researcher Foundation Early Career Award Program Grant, the National Health and Medical Research Council (NHMRC) of Australia: Project Grant (APP1046036) and NHMRC fellowships awarded to MM (APP1061704) and DJP (APP1144544). KPB is supported by Women’s and Children’s Hospital Foundation, MS McLeod Post-doctoral Fellowship. DCS is supported by The Australian Government Research Training Program Scholarship from The University of Adelaide.
Data Availability
Data will be available to Researchers who provide a methodologically sound research proposal following review and approval by the trial steering committee and completion of a signed data access agreement. Following approval, de‐identified, individual participant data that underlie the results reported in this article (text, tables, figures and appendices) and/or dataset(s) will be limited to those participants and variables that are necessary for completion of the approved research proposal. Data sharing requests for de‐identified raw data should be made to the trial steering committee and can be submitted to karen.best{at}sahmri.com
Abbreviations
- UMFA
- unmetabolized folic acid
- NTDs
- neural tube defects
- DHFR
- dihydrofolate reductase
- IgE
- Immunoglobulin-E
- SPT
- skin prick test
